Biography
Mann's research interests include developing molecular therapies – treatments that target specific cells involved in disease – for disorders of the heart and lungs. While on the faculty at Harvard Medical School, he designed and directed the first clinical program for genetic manipulation during bypass surgery.
Mann earned his medical degree at the Stanford University School of Medicine. He completed a residency at Stanford Medicine and Brigham and Women's Hospital in Boston, followed by a fellowship at UCSF.
Education
Institution | Degree | Dept or School | End Date |
---|---|---|---|
University of California, San Francisco | Residency | Cardiothoracic Surgery | 2003 |
Harvard Medical School/Brigham and Women's Hospital | Residency | General Surgery | 2001 |
Stanford University | M.D. | School of Medicine | 1991 |
Princeton University | AB | Chemistry | 1985 |
Board Certifications
American Board of Surgery
American Board of Thoracic Surgery
Clinical Expertise
Bronchioloalveolar Carcinoma (BAC)
Carcinoid Tumors
Chest Wall Tumors
Esophageal Cancer
Esophagectomy
Lung Metastases
Lung Transplantation
Lung Volume Reduction Surgery
Malignant Mesothelioma
Mediastinal Masses
Minimally Invasive Thoracic Surgery
Non-Small Cell Lung Cancer
Sarcomas
Small-Cell Lung Cancer
Tracheal Tumors
Video-Assisted Thoracoscopic Surgery (VATS)
Foreign Languages Spoken
Program Affiliations
Thoracic Oncology Program
UCSF Helen Diller Family Comprehensive Cancer Center
Heart and Lung Transplantation Program
UCSF Cardiovascular Research Institute
In the News
Grants and Funding
- ERK Signaling and a Hybrid Surgical/Molecular Approach for Chronic Heart Failure | NIH | 2005-12-01 - 2017-04-30 | Role: Principal Investigator
- The role of S1P signaling in surgical cardiac remodeling | NIH | 2006-04-01 - 2012-03-31 | Role: Principal Investigator
- GROWTH FACTOR EXPRESSION IN VEIN GRAFT STENOSIS | NIH | 1993-10-28 - 1900-01-01 | Role: Principal Investigator
Research Narrative
The Cardiothoracic Translational Research Laboratory is focused on turning a deeper understanding of the complex biology of cancer and heart failure into a new generation of cellular and molecular therapies. The lab’s cancer research focuses on untangling the mystery of metastasis, a pathologic phenomenon that remains both poorly understood and still responsible for most cancer deaths. Heart failure, in turn, affects more than 5 million Americans and is already the greatest single economic burden in American health care, yet no existing therapies can either halt or reverse the disease process.
Michael J. Mann, M.D. is the Lab Director. His group is analyzing the molecular basis of metastasis to the lungs through careful analysis of human tumor specimens. Via comparison of the complex molecular responses of both primary cancers in their original locations and metastatic lesions in the same patients, they have begun to reveal a pattern of gene activity that may yield both more precise diagnosis of and revolutionary new therapies for metastatic disease.
The Cardiac wing of the Translational Research Lab has been studying the molecular underpinnings of heart failure over the past decade, and has made several fundamental observations regarding the balance of molecular signals that can push a heart either toward compensatory adaptation or relentless failure. By combining cutting edge reconstructive surgery with novel molecular intervention, the group hopes to provide a strong scientific foundation for the clinical development of unprecedented human therapies.
Research Interests
Biomarkers and molecular profiling of metastasis
Molecular biology of metastasis
Molecular biology of sarcomas
Clinical management of pulmonary metastasis
Clinical management of sarcoma
Evolving techniques for minimally invasive chest surgery
Cardiovascular cell cycle biology
Cardiovascular tissue engineering
Molecular and stem cell biology
Molecular genetics of heart disease
Myocardial gene therapy
Stem and progenitor cell transplantation for cardiovascular regeneration
Therapeutic neovascularization for ischemic disease
Personalized Medicine
Publications
- The impact of adjuvant EGFR-TKIs and 14-gene molecular assay on stage I non-small cell lung cancer with sensitive EGFR mutations.| | View in PubMed
- Caffeine consumption and onset of alcohol use among early adolescents.| | View in PubMed
- Genetic and immunologic features of recurrent stage I lung adenocarcinoma.| | View in PubMed
- Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay.| | View in PubMed
- Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy.| | View in PubMed
- Resectability, Recurrence, and Risk Stratification of Giant Solitary Fibrous Tumors in the Thoracic Cavity.| | View in PubMed
- MO01.13 Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit from Adjuvant Chemotherapy.| | View in PubMed
- Comparison of Conventional TNM and Novel TNMB Staging Systems for Non-Small Cell Lung Cancer.| | View in PubMed
- MA06.09 Timing of Driver Mutation Development and the Genetic Evolution of Semi-Solid Lung Nodules into Early NSCLC.| | View in PubMed
- Differential gene expression identifies KRT7 and MUC1 as potential metastasis-specific targets in sarcoma.| | View in PubMed
- Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging.| | View in PubMed
- P2.16-12 Expanded Data Confirm Molecular Testing Identifies Lung Adenocarcinoma Patients, Including Stage IA, Who Benefit from Adjuvant Chemotherapy.| | View in PubMed
- P3.03-24 Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging.| | View in PubMed
- Propensity Matched Analysis of Perioperative Outcomes in Robotic-Assisted Thoracic Surgery, Video Assisted Thoracic Surgery, and Open Lung Resections.| | View in PubMed
- A review of soft-tissue sarcomas: translation of biological advances into treatment measures.| | View in PubMed
- Shift toward greater pathologic post-myocardial infarction remodeling with loss of the adaptive hypertrophic signaling of alpha1 adrenergic receptors in mice.| | View in PubMed
- Atrial ERK1/2 activation in the embryo leads to incomplete Septal closure: a novel mouse model of atrial Septal defect.| | View in PubMed
- Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer.| | View in PubMed
- OA19.06 Adjuvant Chemotherapy Decisions Based on Molecular Risk Status Improves Outcomes in Early Stage, Non-Small Cell Lung Cancer.| | View in PubMed
- P1.03-066 Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer TNM Staging Topic: Staging.| | View in PubMed
- Spacial and Temporal Patterns of Gene Expression After Cardiac MEK1 Gene Transfer Improve Post-Infarction Remodeling Without Inducing Global Hypertrophy.| | View in PubMed
- Genistein Suppresses Growth of Human Uterine Sarcoma Cell Lines via Multiple Mechanisms.| | View in PubMed
- Prognostic molecular assay might improve identification of patients at risk for recurrence in early-stage non-small-cell lung cancer.| | View in PubMed
- Aggressive and minimally invasive surgery for pulmonary metastasis of sarcoma.| | View in PubMed
- VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer.| | View in PubMed
- Novel video-assisted thoracoscopic surgery metastatectomy technique equivalent to open thoracotomy for identification of numerous and small lesions.| | View in PubMed
- Analytical validation of a practical molecular assay prognostic of survival in nonsquamous non-small cell lung cancer.| | View in PubMed
- International trial of adjuvant therapy in high risk stage I non-squamous cell carcinoma identified by a 14-gene prognostic signature.| | View in PubMed
- Impact of a multigene prognostic assay on postoperative management of early-stage non-small cell lung cancer.| | View in PubMed
- Prognostic assay in small, node-negative non-small cell lung cancer--reply.| | View in PubMed
- MEK1-induced physiological hypertrophy inhibits chronic post-myocardial infarction remodeling in mice.| | View in PubMed
- A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors.| | View in PubMed
- Pulmonary metastasectomy: Improving survival with less invasive, more aggressive surgery.| | View in PubMed
- A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies.| | View in PubMed
- IL11 is prognostic of survival in lung adenocarcinoma.| | View in PubMed
- Stem Cell Transplantation to the Heart.| | View in PubMed
- Biomimetic matrices for myocardial stabilization and stem cell transplantation.| | View in PubMed
- Distinctive ERK and p38 signaling in remote and infarcted myocardium during post-MI remodeling in the mouse.| | View in PubMed
- Heart Failure Switches RV Inotropic Responses from Negative to Positive.| | View in PubMed
- Heart failure switches the RV alpha1-adrenergic inotropic response from negative to positive.| | View in PubMed
- Myocardial survival signaling in response to stem cell transplantation.| | View in PubMed
- Sphingolipid signaling and treatment during remodeling of the uninfarcted ventricular wall after myocardial infarction.| | View in PubMed
- Surgical ventricular reconstruction in mice: elucidating potential targets for combined molecular/surgical intervention.| | View in PubMed
- Cardiac transgenic matrix metalloproteinase-2 expression induces myxomatous valve degeneration: a potential model of mitral valve prolapse disease.| | View in PubMed
- National Institutes of Health funding for cardiothoracic surgical research.| | View in PubMed
- National institutes of health funding for surgical research.| | View in PubMed
- Transcription factor decoys: a new model for disease intervention.| | View in PubMed
- Use of bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia.| | View in PubMed
- Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia.| | View in PubMed
- Cell cycle-dependent regulation of smooth muscle cell activation.| | View in PubMed
- Isolated pulmonary arteriovenous malformations requiring anatomic resection.| | View in PubMed
- Novel strategies for the prevention of bypass graft failure.| | View in PubMed
- Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy.| | View in PubMed
- Transcription factor decoys for the prevention of vein bypass graft failure.| | View in PubMed
- Molecular approaches for the treatment of atherosclerosis.| | View in PubMed
- Endothelial healing in vein grafts: proliferative burst unimpaired by genetic therapy of neointimal disease.| | View in PubMed
- Experimental Models of Arteriovenous Grafting.| | View in PubMed
- Gene Therapy in Cardiovascular Disease.| | View in PubMed
- Vascular growth factors as an adjunct to surgical revascularization.| | View in PubMed
- DNA transfer into vascular smooth muscle using fusigenic Sendai virus (HJV)-liposomes.| | View in PubMed
- 901-90 In Vivo Genetic Engineering of Cardiac Cells: Intracoronary Administration of Antisense (AS) Oligonucleotides (ODN).| | View in PubMed
- 914-71 High Efficiency Gene Transfer into Atherosclerotic Lesions in Hypercholesterolemic Rabbit Carotid Arteries.| | View in PubMed